Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1993 March; 67(3): 568–572.
PMCID: PMC1968255

Salvage treatment in male patients with germ cell tumours.


The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > or = 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients).

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (910K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aass N, Fosså SD, Ous S, Stenwig AE, Lien HH, Paus E, Kaalhus O. Prognosis in patients with metastatic non-seminomatous testicular cancer. Radiother Oncol. 1990 Apr;17(4):285–292. [PubMed]
  • Basheda SG, Gephardt G, Meeker DP. The growing teratoma syndrome. Chest. 1991 Jul;100(1):259–260. [PubMed]
  • Broun ER, Nichols CR, Tricot G, Loehrer PJ, Williams SD, Einhorn LH. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant. 1991 Jan;7(1):53–56. [PubMed]
  • Cassidy J, Lewis CR, Kaye SB, Kirk D. The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer. 1992 Jan;65(1):127–129. [PMC free article] [PubMed]
  • Dearnaley DP, Horwich A, A'Hern R, Nicholls J, Jay G, Hendry WF, Peckham MJ. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer. 1991;27(6):684–691. [PubMed]
  • Droz JP, Pico JL, Ghosn M, Gouyette A, Baume D, Piot G, Ostronoff M, Theodore C, Beaujean F, Hayat M. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer. 1991;27(7):831–835. [PubMed]
  • Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E, 3rd, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul;8(7):1239–1245. [PubMed]
  • Fosså SD, Saeter G, Aass N, Ous S, Stenwig AE, Blomlie V. Management of patients with poor-prognosis nonseminomatous germ cell cancer. Oncology. 1990;47(3):234–240. [PubMed]
  • Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol. 1991 Sep;9(9):1549–1555. [PubMed]
  • Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, Peckham MJ, Hendry WF. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol. 1991 Jan;9(1):62–69. [PubMed]
  • Jansen RL, Sylvester R, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, Keizer J, van Oosterom AT, Meyer S, Vendrik CP, et al. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer. 1991;27(6):695–698. [PubMed]
  • Longo DL, Duffey PL, DeVita VT, Jr, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol. 1991 Nov;9(11):2042–2051. [PubMed]
  • Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, Scher HI, Herr H, Fair W, Morse M, et al. Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer. 1990 Jun 1;65(11):2465–2470. [PubMed]
  • Motzer RJ, Geller NL, Tan CC, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer. 1991 Mar 1;67(5):1305–1310. [PubMed]
  • Stoter G, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CP, Spaander P, de Pauw M, Sylvester R. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1986 Aug;4(8):1199–1206. [PubMed]
  • Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435–1440. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK